Search Results
Your search for ,WHo matches 20416 pages
Showing 19451 - 19500More Than 50% of Older, Sick Adults Receive Cancer Screenings Unlikely to Provide Benefit
Despite updates on cancer screening guidelines from several medical societies—including ASCO, the American Cancer Society, the American Urological Association, the American College of Physicians, as well as the U.S. Preventive Services Task Force—which use life expectancy and/or age as...
Analysis of Randomized Bisphosphonate Osteoporosis Trials Indicates No Reduction in Risk of Postmenopausal Breast Cancer
Observational studies have suggested a potential effect of bisphosphonate treatment for osteoporosis in reducing risk of breast cancer in postmenopausal women. However, an analysis of the randomized FIT trial of alendronate and HORIZON-PFT trial of zoledronic acid reported in JAMA Internal Medicine ...
Body Mass Index Positively Associated With Many Cancers in UK Study
In a UK population-based cohort study of associations between body mass index (BMI) and 22 specific cancers reported in The Lancet by Bhaskaran et al, positive associations were found for most cancers and were strongest for uterine, gallbladder, kidney, cervix, thyroid, liver, colon, ovarian, and...
Oncologists Respond Rapidly to Clinical Trial Evidence on Use of EGFR Inhibitors
Use of panitumumab (Vectibix) and cetuximab (Erbitux) in patients with metastatic colorectal cancer decreased significantly after the publication of clinical trial evidence that anti-EGFR antibodies should be restricted to wild-type KRAS tumors, subsequent ASCO guidelines recommending testing for...
More Accurate Identification of Molecular Subgroups May Better Guide Neoadjuvant Treatment of Breast Cancer
BluePrint in combination with MammaPrint molecular subtyping reclassified more than 20% of breast cancer patients into a different subgroup compared with conventional assessment, according to the results of the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). In Annals of Surgical...
NeoALTTO Trial Shows No Benefit of Lapatinib Plus Trastuzumab in Secondary Survival Endpoints in HER2-Positive Early Breast Cancer
The phase III NeoALTTO trial showed a significantly improved pathologic complete response rate with lapatinib (Tykerb) plus trastuzumab (Herceptin) vs either alone in women with HER2-positive early breast cancer. As reported in The Lancet Oncology by de Azambuja et al, the combination was not...
ALK-Positivity Prevalence on Immunohistochemistry and FISH in Resected Stage I to III Lung Adenocarcinoma
The European Thoracic Oncology Platform Lungscape ALK project is investigating the prevalence and prognostic impact of ALK-positivity in resected lung adenocarcinoma in a primarily European population. As reported in the Journal of Clinical Oncology by Blackhall and colleagues, the project has...
NORCCAP Trial Shows Reduced Colorectal Cancer Incidence and Mortality With Flexible Sigmoidoscopy Screening at 11-Year Follow-up
The Norwegian Colorectal Cancer Prevention Trial comparing colorectal cancer screening with flexible sigmoidoscopy vs no screening showed no reduction in colorectal cancer incidence or mortality after 7 years of follow-up. As reported by Holme et al in JAMA, the 11-year follow-up shows significant...
FDA Approves Bevacizumab for Aggressive and Late-Stage Cervical Cancer
The U.S. Food and Drug Administration (FDA) has approved the antiangiogenic agent bevacizumab (Avastin) for the treatment of persistent, recurrent, or metastatic cervical cancer. The new indication is approved for use in combination with paclitaxel and cisplatin or paclitaxel and topotecan. The FDA ...
ERSPC 13-Year Follow-up: Reduction in Prostate Cancer Mortality With PSA Screening, but High Overdiagnosis Rates Remain a Concern, Say Authors
The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Schröder et al in The Lancet, showed that prostate-specific antigen (PSA) screening in men aged 55 to 69 years is associated with a 21% reduction in risk of prostate cancer mortality...
Similar 30-Day Outcomes With Laparoscopic vs Open Partial Hepatectomy in Single-Center Experience
In a single-center retrospective matched case-control study reported in JAMA Surgery, Franken et al found no significant differences in 30-day morbidity or mortality, positive margin status, major complications, hospital stay, or readmission rates for laparoscopic vs open partial hepatic resection...
Prostate Cancer Prevention Trial Identifies Men Most Likely to Undergo Challenging Study Procedures
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study by Gritz et al published in Cancer Epidemiology, Biomarkers & Prevention. The Prostate Cancer Prevention Trial, ...
NSAID Use May Reduce Risk of Breast Cancer Recurrence in Overweight and Obese Women
Obesity is associated with a worse breast cancer prognosis and elevated levels of inflammation, including greater cyclooxygenase-2 (COX-2) expression and activity in adipose-infiltrating macrophages. Data from a new study finds that overweight and obese women who regularly used aspirin or other...
No Difference in Response Rate but Overall Survival Benefit With First-Line FOLFIRI/Cetuximab vs FOLFIRI/Bevacizumab in Metastatic Colorectal Cancer
In a European phase III FIRE-3 trial reported in The Lancet Oncology, Heinemann et al found no difference in response rate, the primary endpoint, between FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus the anti-EGFR antibody cetuximab (Erbitux) vs FOLFIRI plus the anti-VEGF-A antibody...
Successful Vemurafenib Treatment of Progressive BRAF V600E–Mutated Anaplastic Pleomorphic Xanthoastrocytoma
The BRAF inhibitor vemurafenib (Zelboraf) is approved for treatment of BRAF-mutated metastatic melanoma. There are reports indicating that vemurafenib may be active in the treatment of intracranial neoplasms with BRAF mutations. As reported in the Journal of Clinical Oncology, Lee et al from...
Negative PET/CT After One Cycle of Chemotherapy Strongly Predicts Favorable Outcome in Hodgkin Lymphoma
Negative 18F–fluorodeoxyglucose positron-emission tomography (PET)/computed tomography (CT) after two cycles of chemotherapy (PET2) has been shown to be associated with favorable prognosis in Hodgkin lymphoma. In a prospective study reported in the Journal of Clinical Oncology, Hutchings et...
FDA Approves First Noninvasive DNA Screening Test for Colorectal Cancer
The U.S. Food and Drug Administration (FDA) today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or...
TP53, TET2, and DNMT3A Mutations Predict Poorer Survival After Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndrome
It is unclear whether somatic mutations that are strongly associated with phenotype and prognosis in myelodysplastic syndrome are also predictive of outcome after allogeneic hematopoietic stem cell transplantation. In a study reported in the Journal of Clinical Oncology, Bejar et al found that...
FDA Approves Bortezomib Retreatment in Patients With Multiple Myeloma
The U.S. Food and Drug Administration has approved bortezomib (Velcade) for the retreatment of adult patients with multiple myeloma who had previously responded to bortezomib therapy and relapsed at least 6 months following completion of prior bortezomib treatment. The labeling update includes...
Regular, Moderate Physical Activity Decreases Breast Cancer Risk in Postmenopausal Women
Postmenopausal women who in the previous 4 years had undertaken the equivalent of at least 4 hours of walking per week had a 10% decreased risk of invasive breast cancer compared with women who were less active, according to a new study. The findings suggest that regular physical activity, even of...
Genome-Wide Association Study Finds New Genetic Risk Markers in Pancreatic Cancer
A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, reported scientists from Dana-Farber Cancer Institute. The study by Wolpin et al was published in Nature Genetics. The...
Study Identifies New Gene Fusion in Aggressive Estrogen Receptor–Positive Breast Cancer
Researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine have reported new information about the genetic alterations that may contribute to the development of a breast cancer subtype typically associated with more aggressive forms of the disease and higher recurrence...
FDA Grants Fast Track Designation to Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
The U.S. Food and Drug Administration has granted Fast Track designation to pacritinib for the treatment of intermediate- and high-risk myelofibrosis, including patients with disease-related thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are suboptimally...
Statin Use After Colorectal Cancer Diagnosis Reduces Colorectal Cancer–Specific and All-Cause Mortality
In a UK population-based cohort study reported in the Journal of Clinical Oncology, Cardwell et al found that statin use after diagnosis of colorectal cancer was associated with a 29% reduction in colorectal cancer–specific mortality and a 25% reduction in all-cause mortality. Improvements...
Study Finds Nearly 10% of Cancer Survivors Continue to Smoke Years After Diagnosis
Despite the fact that smoking increases the probability of cancer recurrence and reduces survival time, many cancer survivors continue to smoke. In a new study, nearly 1 in 10 cancer survivors reported being current smokers 9 years after their diagnosis, and 83% were daily smokers averaging about...
Renowned Pathologist Emmanuel Farber, MD, PhD, Dies
Cancer research lost a pioneer on August 3, 2014, with the passing of Emmanuel Farber, MD, PhD, a renowned pathologist who made fundamental contributions to our understanding of chemical carcinogenesis. Dr. Farber’s studies in experimental pathology demonstrated that chemical carcinogens are...
Significant Variation in Use of Single-Fraction Radiation Therapy for Palliation of Bone Metastases
Standardizing prescribing practices for single-fraction radiation therapy for palliation of bone metastases could lead to cost savings and improvement in patients’ quality of life, according to a study published in the August issue of the International Journal of Radiation Oncology •...
Patient Navigation Significantly Improves Receipt of Antiestrogen Therapy but Not Radiation Therapy After Lumpectomy in Breast Cancer Patients
An analysis in the population of the National Patient Navigation Research Program reported by Ko et al in the Journal of Clinical Oncology indicates that patient navigation significantly improves the likelihood of receiving antiestrogen treatment among hormone receptor–positive breast cancer...
Ruxolitinib Granted Priority Review for Polycythemia Vera
The U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi) as a potential treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of...
Blood and Saliva Tests Help Predict Recurrence of HPV-Related Oral Cancer
Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus (HPV) shed from cancer cells lingering in the mouth or other...
High Prevalence of and Shorter Survival With MYD88 Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type
The activating mutation MYD88 L265P has been reported in approximately two-thirds of cases of primary cutaneous diffuse large B-cell lymphoma, leg-type. In a French retrospective analysis reported in JAMA Dermatology, Pham-Ledard et al confirmed the high prevalence of the mutation and documented...
Tumor Downstaging After Neoadjuvant Chemotherapy Strongly Predicts Improved Outcome After Surgery in Esophageal and Esophagogastric Junction Cancer
In a European analysis reported in the Journal of Clinical Oncology, Davies et al found that pathologic tumor downstaging after neoadjuvant chemotherapy was the strongest independent predictor of overall survival in patients undergoing surgery for esophageal and esophagogastric junction...
Study Suggests Recent Use of Some Birth Control Pills May Be Associated With Increased Breast Cancer Risk
Women who recently used birth control pills containing high-dose estrogen and a few other formulations had an increased risk for breast cancer, whereas women using some other formulations did not, according to data published in Cancer Research. “Our results suggest that use of contemporary...
Phase II Trial Shows Activity of Pemetrexed Plus Cisplatin in Treatment of Advanced, Persistent, or Recurrent Cervical Carcinoma
In a phase II Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Miller et al found that the combination of pemetrexed (Alimta) and cisplatin produced responses in the treatment of advanced, persistent, or recurrent cervical cancer. In the study, 54 patients from...
Musculoskeletal Pain May Be Sign of Potential Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML
In a letter to the Journal of Clinical Oncology, Richter et al describe a potential tyrosine kinase inhibitor withdrawal syndrome characterized by musculoskeletal pain after stopping tyrosine kinase inhibitor treatment for chronic myeloid leukemia (CML). Onset After Tyrosine Kinase Inhibitor...
Growth-Driving Cancer Cells May Be Better Targets for Therapy Than Cells That Proliferate the Fastest, Study Suggests
Of the many subgroups of cells vying for control within a cancerous tumor, the most dangerous may not be those that can proliferate the fastest, researchers at Dana-Farber Cancer Institute reported in a study published in Nature. The findings have important implications for the treatment of cancer...
Results of Genomic Analysis Suggest Strategy for Overcoming Ibrutinib Resistance in Mantle Cell Lymphoma
Although the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) has shown unprecedented clinical activity in mantle cell lymphoma, about 32% of patients do not respond to the drug and majority of responders eventually relapse. Genomic sequencing of tumor and healthy tissue from patients...
Minimal Residual Disease–Based Risk-Directed Therapy Is Effective in Children With BCR-ABL1–Like B-Cell ALL
BCR-ABL1–like acute lymphoblastic leukemia (ALL), a recently identified B-cell ALL subtype associated with poor outcome, has a gene-expression profile similar to BCR-ABL1–positive disease without the presence of the BCR-ABL1 fusion protein. In a retrospective analysis reported in the...
Adults With Exclusively Pulmonary Metastases From Ewing Sarcoma May Benefit From Whole-Lung Irradiation
Nearly half of adult patients with lung-only metastases from Ewing sarcoma who received whole-lung irradiation were free of pulmonary relapse at 3 years, according to the results of a retrospective study in the International Journal of Radiation Oncology • Biology • Physics. With few...
Researchers Identify Genetic Mutations Linked to Salivary Gland Tumors
Research conducted at the Florida campus of The Scripps Research Institute (TSRI) has discovered links between a set of genes known to promote tumor growth and mucoepidermoid carcinoma, an oral cancer that affects the salivary glands. The discovery could help physicians develop new treatments that...
Acupuncture Provides Significant Quality-of-Life Improvements Among Breast Cancer Patients With Aromatase Inhibitor–Related Joint Pain
Use of electroacupuncture—a form of acupuncture where a small electric current is passed between pairs of acupuncture needles—produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for early-stage breast cancer patients experiencing joint pain...
African Americans More Likely Than Whites to Receive Analgesic With Toxic Metabolite for Cancer Pain
A study reported by Meghani et al in the Journal of Clinical Oncology showed that African American patients with cancer pain are more likely than white patients to receive morphine, with its known 3- and 6-glucuronide neurotoxic metabolites, despite their higher reported risk for chronic kidney...
Improved Overall Survival With Primary Over Consolidation Intraperitoneal Chemotherapy After Optimal Cytoreduction for Advanced Ovarian Cancer
Compared with intravenous (IV) followed by consolidation intraperitoneal (IP) chemotherapy, primary IV/IP chemotherapy was associated with a statistically significant improvement in overall survival—but not progression-free survival—in patients with advanced epithelial ovarian cancer...
Phase Ib Study Shows Activity of Ibrutinib Plus R-CHOP in First-Line Treatment of CD20-Positive B-Cell Non-Hodgkin Lymphoma
The oral Bruton's tyrosine kinase inhibitor ibrutinib (Imbruvica) has shown activity in relapsed and refractory B-cell malignancies. In a phase Ib trial reported in The Lancet Oncology, Younes et al identified no maximum tolerated dose of ibrutinib when combined with R-CHOP (rituximab [Rituxan],...
Study Helps Compare Risks of Endoscopic vs Surgical Resection for Early Esophageal Cancer
A new study published in the Journal of the National Cancer Institute by researchers at Northwestern Medicine shed new light on the risks associated with the growing popularity of endoscopic resection in the treatment of localized, early-stage esophageal cancer. Merkow et al found that the...
Promising Phase Ib Findings With Combined BRAF and MEK Inhibition With Vemurafenib and Cobimetinib in Advanced BRAF V600–Mutant Melanoma
In a phase Ib study reported in The Lancet Oncology, Ribas et al found that the combination of the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib was safe and active in the treatment of advanced BRAF V600–mutant melanoma. Preclinical studies have shown that the...
Combination Afatinib and Cetuximab Yields Benefit in Lung Cancer Patients Resistant to EGFR Inhibitors
A phase Ib study has found that a combination of the EGFR-targeted agents afatinib (Gilotrif) and cetuximab (Erbitux) yielded clinical responses in patients with EGFR-mutant lung cancer that had stopped responding to the EGFR inhibitors erlotinib (Tarceva) and gefitinib (Iressa). The combination...
Study Identifies Prevalence of Uterine Malignancy and Endometrial Hyperplasia at Time of Morcellation for Hysterectomy
There is considerable concern that uterine morcellation as part of minimally invasive hysterectomy may result in the spread of undetected malignancies. In a study reported in JAMA, Wright et al identified a prevalence of 27 cases of uterine cancer and 7 cases of other gynecologic malignancies per...
Failure to Adopt a Healthy Lifestyle More Than Doubles Risk of Metabolic Syndrome in Childhood Cancer Survivors
A St. Jude Children’s Research Hospital study found that 73% of adult survivors of childhood cancer more than doubled their risk of developing metabolic syndrome and related health problems by failing to follow a heart-healthy lifestyle. The results were published online in the journal...
First Surveillance Imaging at 6 Months May Be Adequate for Most Patients After Treatment for Early-Stage Non‒Small Cell Lung Cancer
Early surveillance imaging (< 6 months) after stereotactic body radiation therapy for early-stage non–small cell lung cancer (NSCLC) seems to be of limited benefit, resulting in definitive intervention in only 3% of patients, according to the findings of a study in Practical Radiation...
